NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Orionis Biosciences

Orionis Biosciences

Private
Waltham, MassachusettsHealthcare & Life Scienceshttps://orionisbio.com/

Last Round

Corporate Funding

May 21, 2025

Total Funding Raised

$111M

Company Overview

Orionis Biosciences is a life sciences company that develops precision therapies for life-threatening diseases using its proprietary Allo-Glue and A-Kine technology platforms.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Infrastructure

Keywords

drug discoverymolecular gluecytokine engineeringprecision medicineAI drug discoverybiotech platformAI-driven chemistryundruggable targetstherapeutic developmentin-silico discoverycomputational biologypharma R&Ddrug designtechbioAI-native biotech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Orionis Biosciences Comps

Public and private peers based on sector, stage, and business model.

Orionis Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Orionis Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Corporate FundingMay 21, 2025
Corporate FundingSep 20, 2023
Series COct 19, 2022
Convertible DebtMar 5, 2020
Series BApr 1, 2018
Series B
Mar 1, 2018

Key People

Founding team and executive leadership

Nikolai Kley

Founder, President and CEO

Founding Team

Orionis Biosciences Investors

Notable investors and investment history

Orionis Biosciences investors
InvestorRounds
Cormorant Asset ManagementSeries C
Cascade InvestmentSeries B
GenentechCorporate Funding
Fidelity Management & Research CompanySeries B
V-Bio VenturesSeries A
Excel Venture ManagementSeries A
Nextech InvestSeries B

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 21, 2025

    Second multi-year deal valued at over $2 billion for molecular glue development.

  • Oct 19, 2022

    $55M round led by Cormorant Asset Management and Novartis.

Orionis Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Orionis Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Orionis Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersWaltham, Massachusetts
Employee Range61
Year Founded2015
Last FundingMay 21, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.